Merck reported strong financial results with 7% top-line growth and 10% non-GAAP EPS growth, exceeding expectations. The launch of new products like VICTRELIS and expansions in emerging markets signal positive momentum. Additionally, cost-saving initiatives and strategic partnerships are likely to bolster investor confidence in the short term.

[1]